On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Cannabics Pharmaceuticals, Inc. (CNBX) Proprietary Medical Marijuana Formulation is Ideally Suited for Broad Applications

Our scientific understanding of the efficacy of active cannabinoids from the cannabis plant, like THC, the primary psychoactive component, and CBD, a non-psychoactive component, has been systematically hampered by legislation for decades. As a growing body of medical and now even clinical data on the pharmacology of cannabinoids and the human body’s endocannabinoid system emerges however, in the U.S. alone, laws restricting marijuana, especially medical marijuana (MMJ), have been falling left and right. Minnesota and New York have recently both approved some form of MMJ legislation and MMJ is now legal in 23 states, as well as D.C., opening up a massive market opportunity, with companies like GW Pharmaceuticals (NASDAQ: GWPH) already seeing considerable upside from their growing pipeline of cannabinoid indications, like their Multiple Sclerosis spasticity and neuropathic pain drug Sativex®.

One of the major areas of cannabinoid research today is in treating neurological disorders and their effects, with a recent high-water mark being seen in the FDA approval of a CBD study in childhood epilepsy at the Comprehensive Epilepsy Center of New York University. This clinical trial of CBD in epilepsy would put highly quantified data down to extend the growing acceptance of MMJ, expanding data points like the successful use of the CBD-rich and essentially non-psychoactive Charlotte’s Web strain of cannabis to treat Dravet Syndrome (a form of severe and intractable epilepsy) in the Charlotte Figi case. The dramatic reduction of crippling seizures seen in the case of this one eight-year-old girl, whose story was made famous by chief of neurosurgery at Atlanta’s Grady Memorial Hospital, Dr. Sanjay Gupta, is one of the watershed moments in the MMJ industry and seemed to many in the medical community to validate earlier studies done by Stanford University showing an 84% seizure frequency reduction rate in children treated with a variety of (artisanal) CBD.

The growing understanding of the endocannabinoid system, as well as the crucial effects the CB1 and CB2 receptors play in regulating multiple neurological and physiological processes within the body, has led to growing acceptance in the medical community of MMJ and sparked a firestorm of pharmacological development work in CBD by numerous companies. The palliative care market in cancer alone for instance is huge, with tolerability of even chronic MMJ usage a leading factor among pain relief vectors helping to establish overall acceptance. Established opioid developers like (NASDAQ: CARA) are even getting into the game, developing products like their CR701 compound for neuropathic bodily pain as an alternative to comparably dangerous opioids, which may not even work for some patients who have opioid resistant pain.

One of the smaller hot properties in the burgeoning MMJ field today, and one which already has a functional orally-administered cannabinoid product, Cannabics Pharmaceuticals (OTCQB: CNBX), is a superb way for investors to get in on the action. CNBX’s flagship indication, Cannabics SR, is ideally suited to states in the U.S. like Minnesota, where only non-smokable MMJ preparations are currently permitted. Cannabics SR is a proprietary preparation of pure cannabinoids in capsule form designed for cancer patients as palliative care, yet its ingredients have immediate and broader applications as well, applications that are becoming increasingly apparent to healthcare professionals throughout the industry. Cannabics SR has been shown in observational studies to provide a solid 10 to 12 hours of steady-state therapeutic effects, making it an ideal indication for a safe and convenient once-daily dosing regimen.

Cannabics Pharmaceuticals has specifically developed Cannabics SR to deliver an effective one-two punch, using a dual delivery of oil-based compounds in order to provide both quick onset of therapeutic effects within the first 20 to 60 minutes, as well as long-lasting relief via a more concentrated cannabinoid portion within the capsule. This proprietary, sustained release formulation is prepared in GMP (Good Manufacturing Practices) certified facilities and the company has received certification from the Israeli Ministry of Health for an advanced R&D laboratory dedicated to cannabinoid science as well, a lab which they intend to utilize in pursing the cannabinoid-based anti-cancer therapy end of the spectrum further. The company has recently engaged with Mountain High Products LLC, Owner of the “WANA edibles” brand, for the commercialization of its products in the booming Colorado MMJ market. The company has also recently secured an IP licensing and collaboration agreement for the production and distribution of Cannabics SR in Spain with established regional entity Kalapa Holding, which has made a name for itself advancing a tailored medical cannabis therapy approach to the market, emphasizing direct connections between patients and doctors. Cannabics Pharmaceuticals is at the forefront of commercializing clinically tested cannabis-based products and is currently on-track to launch a series of clinical studies in leading medical centers across Israel, where the company’s R&D division is strategically located

With the domestic MMJ market estimated at around $2B annually by IBISWorld, on a CAGR of around 16.2%, CNBX’s move to tackle not just the U.S. market, but the EU and elsewhere, should make investor’s ears perk up. GlobalData pegs the neuropathic pain market alone at around just under $3B, with a projected CAGR of 3.19% through 2022, when they estimate the market will have grown to approximately $3.5B. Needless to say, there is a massive, target-rich environment for CNBX’s advanced cannabinoid medicines both at home and abroad, and as their pipeline develops further amid prevailing legislative acceptance of MMJ, shareholders stand poised to reap the rewards, while also helping patients in dire need.

To learn more about Cannabics Pharmaceuticals, visit: www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Archives

Select A Month
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered